Does Horizon Blue Cross Blue Shield of New Jersey Cover Eliquis?

How Horizon BCBSNJ Classifies Eliquis on Its Formulary

Horizon Blue Cross Blue Shield of New Jersey maintains several formulary lists across its commercial HMO, PPO, EPO, and Medicare Advantage product lines. Eliquis (apixaban) appears on the majority of these formularies as a preferred brand medication, which typically corresponds to Tier 2 or Tier 3 in Horizon's multi-tier structure.

Commercial Plan Tiers

On most Horizon commercial plans, Eliquis sits at the preferred brand tier. This means it costs less than non-preferred brands but more than generics. A 30-day supply at the preferred brand tier generally carries a copay between $35 and $90 for Horizon members, though high-deductible health plans (HDHPs) require members to meet the deductible before copay pricing applies.

Medicare Advantage Placement

Horizon's Medicare Advantage plans, marketed as Horizon Blue Medicare, also cover Eliquis. The Centers for Medicare & Medicaid Services (CMS) requires Medicare Part D and Medicare Advantage plans with prescription drug coverage to include at least two anticoagulants in their formularies. Eliquis is typically included as a Tier 3 preferred brand in these plans, with cost-sharing that varies by coverage phase (initial, gap, catastrophic). The 2025 Medicare Part D redesign capped annual out-of-pocket drug spending at $2,000, a change that significantly benefits patients taking brand-name anticoagulants long-term [1].

Why Tier Placement Matters

Tier assignment directly controls what you pay. A study published in Health Affairs found that moving a medication up by one formulary tier increased patient abandonment rates by 33%, underscoring how tier placement shapes real-world adherence [2]. If Eliquis is placed on a non-preferred tier in a specific Horizon sub-plan, your out-of-pocket cost could double compared to the preferred tier.

Prior Authorization and Step Therapy Requirements

Most Horizon BCBSNJ commercial plans do not require prior authorization (PA) for Eliquis when prescribed for FDA-approved indications. This is consistent with a broader trend: the American Heart Association (AHA) has recommended that insurers minimize PA barriers for direct oral anticoagulants (DOACs) given the stroke-prevention urgency in atrial fibrillation patients [3].

When Prior Authorization Applies

PA requirements are more common in Horizon Medicare Advantage plans. CMS permits Medicare Part D sponsors to apply utilization management tools, including PA and quantity limits, to control costs. If your Horizon Medicare plan requires PA for Eliquis, your prescribing physician will need to submit clinical documentation confirming an FDA-approved indication, such as non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE).

Step Therapy Considerations

Some Horizon plans impose step therapy, requiring a trial of warfarin before approving Eliquis. The clinical rationale for this approach is debatable. The ARISTOTLE trial (N=18,201) demonstrated that apixaban 5 mg twice daily reduced the rate of stroke or systemic embolism by 21% compared to warfarin (1.27% vs. 1.60% per year; P=0.01), with 31% lower major bleeding (2.13% vs. 3.09% per year; P<0.001) [4]. The 2019 AHA/ACC/HRS atrial fibrillation guidelines give DOACs a Class I recommendation over warfarin for eligible NVAF patients [5]. If your Horizon plan denies Eliquis due to step therapy, your physician can file a formulary exception citing these guidelines.

What Eliquis Costs on a Horizon Plan

The retail price of Eliquis without insurance averages approximately $600 to $650 for a 30-day supply of 5 mg twice daily. With Horizon coverage, out-of-pocket costs drop substantially, but the exact amount depends on your plan's benefit design.

Commercial Plan Cost Estimates

For a standard Horizon PPO or HMO plan with a preferred brand copay, expect to pay $35 to $90 per month. Members enrolled in HDHPs will pay the full negotiated rate until the deductible is satisfied. After meeting the deductible, coinsurance (typically 20% to 30%) applies until the out-of-pocket maximum is reached.

Manufacturer Copay Card

Bristol Myers Squibb and Pfizer, the co-marketers of Eliquis, offer a copay savings card that can reduce the monthly cost to as low as $10 for commercially insured patients. This card is not valid for Medicare, Medicaid, or other federal healthcare program beneficiaries. A 2022 analysis in the Journal of the American Heart Association found that manufacturer copay assistance improved 12-month DOAC adherence by 8.3 percentage points [6].

Medicare Coverage Phases

For Horizon Medicare Advantage members, Eliquis costs fluctuate across Part D coverage phases. During the initial coverage phase, expect a copay of $42 to $100. The Inflation Reduction Act provisions that took effect in 2025 introduced a $2,000 annual out-of-pocket cap for Part D, eliminating the prior catastrophic coverage gap that forced some patients to pay thousands before reaching catastrophic coverage [7].

Clinical Evidence Supporting Eliquis Coverage

Horizon BCBSNJ's decision to include Eliquis on its formularies aligns with strong clinical trial data and national guideline recommendations. Understanding this evidence helps patients and providers advocate for coverage if access barriers arise.

ARISTOTLE Trial

The landmark ARISTOTLE trial randomized 18,201 patients with atrial fibrillation and at least one additional stroke risk factor to apixaban 5 mg twice daily or dose-adjusted warfarin. Apixaban reduced stroke or systemic embolism by 21% (hazard ratio 0.79; 95% CI, 0.66 to 0.95), lowered major bleeding by 31%, and decreased all-cause mortality by 11% (3.52% vs. 3.94%; P=0.047) [4].

AMPLIFY Trial for VTE

The AMPLIFY trial (N=5,395) compared apixaban to standard enoxaparin/warfarin therapy for acute venous thromboembolism. Apixaban was non-inferior for recurrent VTE (2.3% vs. 2.7%) and caused 69% less major bleeding (0.6% vs. 1.8%; P<0.001) [8]. This trial supported the FDA's approval of apixaban for DVT and PE treatment.

ADVANCE Trials for Surgical Prophylaxis

Three ADVANCE trials established apixaban's efficacy for VTE prophylaxis after hip and knee replacement surgery. ADVANCE-3 (N=5,407) showed apixaban 2.5 mg twice daily reduced VTE by 64% compared to enoxaparin 40 mg daily after total hip replacement (1.4% vs. 3.9%; P<0.001) [9]. These data support the American College of Chest Physicians (ACCP) guidelines recommending pharmacologic thromboprophylaxis for 35 days after hip arthroplasty [10].

Real-World Outcomes Data

Beyond randomized trials, large observational studies reinforce apixaban's safety profile. A 2022 FDA post-marketing analysis using data from over 400,000 Medicare beneficiaries found that apixaban had the lowest rate of major bleeding among all DOACs: 2.1 per 100 person-years compared to 2.8 for rivaroxaban and 2.4 for dabigatran [11]. A separate study in Annals of Internal Medicine confirmed lower rates of GI bleeding with apixaban versus rivaroxaban (HR 0.71, 95% CI 0.57 to 0.89) [12].

Alternatives Covered by Horizon BCBSNJ

If cost or formulary restrictions make Eliquis access difficult, Horizon covers several alternative anticoagulants. Each has distinct clinical tradeoffs.

Warfarin

Warfarin is available as a low-cost generic ($4 to $15 per month) and sits on the lowest formulary tier across all Horizon plans. It requires regular INR monitoring, typically every 2 to 4 weeks, and has significant food and drug interactions. The American College of Cardiology notes that approximately 40% of warfarin-treated patients spend significant time outside the therapeutic INR range of 2.0 to 3.0, which compromises both efficacy and safety [13].

Rivaroxaban (Xarelto)

Rivaroxaban is also covered on most Horizon formularies at a similar tier to Eliquis. The ROCKET AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AF (2.1% vs. 2.4% per year; P<0.001 for non-inferiority) [14]. Rivaroxaban has once-daily dosing (an adherence advantage) but higher GI bleeding rates than apixaban.

Edoxaban (Savaysa)

Edoxaban appears on some Horizon formularies, often at a non-preferred tier. The ENGAGE AF-TIMI 48 trial (N=21,105) demonstrated non-inferiority to warfarin for stroke prevention, with lower bleeding [15]. Edoxaban's labeled restriction (do not use in patients with CrCl >95 mL/min due to reduced efficacy) limits its applicability.

How to Verify Your Specific Horizon Coverage

Formulary placement can vary between Horizon plan types and may change at annual renewal. Take these steps to confirm your coverage.

Check the Horizon Drug Formulary Online

Horizon BCBSNJ publishes searchable formulary tools on its member portal. Log in at HorizonBlue.com, manage to the prescription drug section, and search for "apixaban" or "Eliquis." The result will show the tier, any PA or step therapy requirements, and quantity limits specific to your plan.

Call Member Services

The phone number on the back of your Horizon ID card connects you to a representative who can confirm real-time formulary details. Ask specifically whether Eliquis requires PA, whether step therapy applies, and what your copay or coinsurance will be at the preferred brand tier.

Request a Formulary Exception

If Eliquis is not covered or is placed on a non-preferred tier in your plan, your prescribing physician can submit a formulary exception request. The Endocrine Society and AHA both recommend that providers include trial-specific data (ARISTOTLE, AMPLIFY) when justifying medical necessity for DOACs over warfarin [16]. Horizon must respond to standard exception requests within 72 hours and expedited requests within 24 hours, per CMS regulations for Medicare plans [17].

Explore Patient Assistance Programs

Beyond the manufacturer copay card, the Bristol Myers Squibb Patient Assistance Foundation provides free Eliquis to uninsured or underinsured patients who meet income requirements (generally at or below 300% of the federal poverty level). Applications are available through the BMS website.

Dosing and Monitoring Basics for Eliquis

Understanding standard Eliquis dosing helps you anticipate prescription costs and refill frequency under your Horizon plan.

Standard Doses

The FDA-approved prescribing information specifies two primary dosing regimens: 5 mg twice daily for stroke prevention in NVAF, and 2.5 mg twice daily for patients who meet at least two of three dose-reduction criteria (age 80 years or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) [18]. For VTE treatment, the regimen is 10 mg twice daily for 7 days followed by 5 mg twice daily.

Monitoring Requirements

Unlike warfarin, Eliquis does not require routine coagulation monitoring. The American Society of Hematology (ASH) 2020 guidelines on VTE management confirm that DOACs including apixaban do not need regular lab monitoring under standard use [19]. This reduces the total cost of anticoagulation therapy and minimizes office visits, which is relevant when calculating the true cost comparison between warfarin and Eliquis under a Horizon plan.

Renal Considerations

Apixaban has the lowest renal clearance among DOACs (approximately 27%), making it a preferred choice for patients with moderate renal impairment. The Kidney Disease: Improving Global Outcomes (KDIGO) conference report noted that apixaban may be used in patients with CrCl as low as 15 mL/min, a threshold below which other DOACs are contraindicated [20].

New Jersey State Mandates Affecting Coverage

New Jersey has specific insurance regulations that can influence how Horizon BCBSNJ covers prescription drugs.

Mental Health Parity and Prescription Access

While New Jersey's parity laws primarily address behavioral health, the state's Department of Banking and Insurance (DOBI) enforces regulations requiring that fully insured plans provide prescription drug coverage consistent with medical necessity standards. If a physician documents that Eliquis is medically necessary (e.g., warfarin intolerance, labile INR, inability to attend INR monitoring), Horizon is obligated to review a coverage appeal under these standards.

External Review Rights

New Jersey law gives members the right to an independent external review if Horizon denies a formulary exception request. This process is administered through DOBI and involves an independent review organization evaluating the clinical evidence. Given the weight of ARISTOTLE and AMPLIFY trial data, external reviews for Eliquis coverage denials frequently result in overturned decisions.

Apixaban 5 mg twice daily remains the guideline-preferred anticoagulant for most patients with non-valvular atrial fibrillation per the 2023 ACC/AHA/ACCP/HRS AF management guideline, which gives DOACs a Class I, Level of Evidence A recommendation over warfarin in CHA₂DS₂-VASc-eligible patients [21].